An inhibitor of oxidative phosphorylation exploits cancer vulnerability

By J. Molina, Yuting Sun, Marina Protopopova, S. Gera, Madhavi Bandi, C. Bristow, Timothy J. McAfoos, Pietro Morlacchi, J. Ackroyd, Ahmed-Noor A. Agip and 56 more. Nature Medicine, 2018

808 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c26bbdc13b70d246e89b0e096360ed0420deed23

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. B. Faubert
2. Ashley Solmonson
3. Ralph J. Deberardinis
4. M. V. Vander Heiden
5. C. V. Dang
6. Navdeep S. Chandel

In Molecular Biology

1. B. Faubert
2. Ashley Solmonson
3. Ralph J. Deberardinis
4. M. V. Vander Heiden
5. C. V. Dang

Citations in the corpus

• Metabolic reprogramming and cancer progression (2020, background): “Recently described OXPHOS inhibitors display enhanced toxicity against cultured cancer cells compared with either nontransformed cells or other cancer cells with metabolic properties that allow them to compensate forOXPHOS impairment (116, 117).”